The US Drug Policy Landscape
Total Page:16
File Type:pdf, Size:1020Kb
DRUG POLICY RESEARCH CENTER CHILDREN AND FAMILIES The RAND Corporation is a nonprofit institution that helps improve policy and EDUCATION AND THE ARTS decisionmaking through research and analysis. ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE This electronic document was made available from www.rand.org as a public service INFRASTRUCTURE AND of the RAND Corporation. TRANSPORTATION INTERNATIONAL AFFAIRS LAW AND BUSINESS Skip all front matter: Jump to Page 16 NATIONAL SECURITY POPULATION AND AGING PUBLIC SAFETY Support RAND SCIENCE AND TECHNOLOGY Purchase this document TERRORISM AND Browse Reports & Bookstore HOMELAND SECURITY Make a charitable contribution For More Information Visit RAND at www.rand.org Explore the RAND Drug Policy Research Center View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non- commercial use only. Unauthorized posting of RAND electronic documents to a non-RAND website is prohibited. RAND electronic documents are protected under copyright law. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. For information on reprint and linking permissions, please see RAND Permissions. This product is part of the RAND Corporation occasional paper series. RAND occa- sional papers may include an informed perspective on a timely policy issue, a discussion of new research methodologies, essays, a paper presented at a conference, a conference summary, or a summary of work in progress. All RAND occasional papers undergo rigorous peer review to ensure that they meet high standards for research quality and objectivity. The U.S. Drug Policy Landscape Insights and Opportunities for Improving the View Beau Kilmer, Jonathan P. Caulkins, Rosalie Liccardo Pacula, Peter H. Reuter DRUG POLICY RESEARCH CENTER This research was sponsored by the John D. and Catherine T. MacArthur Foundation and was conducted within the RAND Drug Policy Research Center, a joint endeavor of RAND Health and RAND Infrastructure, Safety, and Environment. Library of Congress Control Number: 2012947920 ISBN 978-0-8330-7699-1 The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. R® is a registered trademark. © Copyright 2012 RAND Corporation Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND documents to a non-RAND website is prohibited. RAND documents are protected under copyright law. For information on reprint and linking permissions, please visit the RAND permissions page (http://www.rand.org/publications/ permissions.html). Published 2012 by the RAND Corporation 1776 Main Street, P.O. Box 2138, Santa Monica, CA 90407-2138 1200 South Hayes Street, Arlington, VA 22202-5050 4570 Fifth Avenue, Suite 600, Pittsburgh, PA 15213-2665 RAND URL: http://www.rand.org To order RAND documents or to obtain additional information, contact Distribution Services: Telephone: (310) 451-7002; Fax: (310) 451-6915; Email: [email protected] Preface Discussions about reducing the harms associated with drug use and antidrug policies are often politicized, infused with questionable data, and unproductive. In this occasional paper, researchers provide a nonpartisan primer on the topic that should be of interest to those who are new to the field of drug policy, as well as those who have been working in the trenches. This project was funded by the John D. and Catherine T. MacArthur Foundation, and the views presented here reflect only those of the authors. This study was conducted under the auspices of the RAND Drug Policy Research Center. The goal of the Drug Policy Research Center is to provide a firm, empirical foundation on which sound drug policies can be built, at the local and national levels. The center’s work is supported by foundations, government agencies, corporations, and individuals. We are indebted to Nicholas M. Pace (RAND) and Harold Pollack (University of Chi- cago) for their constructive reviews. The paper also benefited from comments made by James Burgdorf (RAND), Keith Humphreys (Stanford University), and Sarah Lawrence (University of California, Berkeley). Questions or comments about this paper should be sent to the project leader, Beau Kilmer ([email protected]). Information about the Drug Policy Research Center is available online (http://www.rand.org/multi/dprc/). Inquiries about research projects should be made to the center’s co-directors, Rosalie Liccardo Pacula ([email protected]) and Beau Kilmer ([email protected]). iii Contents Preface ........................................................................................................... iii Figures ...........................................................................................................vii Summary ........................................................................................................ ix Abbreviations ..................................................................................................xiii CHapTER ONE Introduction ..................................................................................................... 1 CHapTER TWO The Drug Policy Landscape in the United States ......................................................... 3 Drug Use .......................................................................................................... 3 Designer Drugs................................................................................................. 5 Drug Problems ................................................................................................... 6 The Economic Burden of Drug Use ......................................................................... 6 Observation 1: Prescription Drugs Account for an Increasing Share of the Nation’s Drug Problem .................................................................................................... 7 Observation 2: Cocaine Accounts for a Decreasing Share of the Nation’s Drug Problem ............ 8 Observation 3: U.S. Demand for Drugs is Fueling Violence and Corruption in Mexico and Central America ........................................................................................... 9 Drug Policy in the United States ..............................................................................10 Government Spending on Drug Policy ....................................................................10 Domestic Law Enforcement .................................................................................10 Interdiction ....................................................................................................11 International Efforts ..........................................................................................12 Prevention ......................................................................................................12 Treatment ......................................................................................................13 Recent Change 1: The Patient Protection and Affordable Care Act (ACA) ...........................13 Recent Change 2: Federal Response to Medical Marijuana .............................................14 CHapTER THREE Efficacy of U.S. Drug Policies and Programs .............................................................17 Supply Reduction ...............................................................................................17 Management of Market-Related Harms .....................................................................19 Treatment ....................................................................................................... 20 Other Interventions with Dependent Users ................................................................. 22 v vi The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View Prevention ....................................................................................................... 23 Topics Meriting Additional Attention ....................................................................... 24 CHapTER FOUR The Drug Policy Research Funding Landscape ..........................................................25 Government Agencies ..........................................................................................25 National Institutes of Health (NIH) .......................................................................25 Substance Abuse and Mental Health Services Administration (SAMHSA) .......................... 26 U.S. Veterans Health Administration (VHA) ............................................................ 26 White House Office of National Drug Control Policy (ONDCP) .................................... 26 U.S. Department of Justice (DOJ) Office of Justice Programs (OJP) ................................. 27 Other Government Agencies ............................................................................... 27 Foundations ..................................................................................................... 27 The Robert Wood Johnson Foundation (RWJF) .......................................................